San Antonio Breast Cancer Symposium | Conference

Dr. Debu Tripathy on Molecular Predictors of Outcome in Breast Cancer

January 28th 2016

Debu Tripathy, MD, professor of Medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses molecular predictors of outcome for patients with ER-positive breast cancer.

Dr. Blackwell on Margetuximab for HER2+ Breast Cancer

January 19th 2016

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.

Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast Cancer

January 18th 2016

Peter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.

Palbociclib Improves Cell Cycle Control in ER-Positive Breast Cancer

December 14th 2015

Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.

Pembrolizumab Continues to Show Promise in Breast Cancer

December 12th 2015

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

Neratinib DFS Benefit Sustained in 3-Year ExteNET Update

December 12th 2015

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

Dr. Patricia Ganz on Anastrozole versus Tamoxifen Side Effects in DCIS Patients

December 11th 2015

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.

IBIS-II: Anastrozole and Tamoxifen Similar on Recurrence, but Toxicity Profiles Differ

December 11th 2015

Breast cancer recurrence was similar whether postmenopausal women with ductal carcinoma in situ received anastrozole or tamoxifen for 5 years following local excision in the IBIS-II trial.

Tamoxifen or Anastrozole? Patient Reports Can Help Decide

December 11th 2015

Patient reports of their experiences with taking either tamoxifen or anastrozole can help clinicians decide which one to recommend to individual women, new research has found.

Dr. Joanne Blum on the EMBRACA Trial in Metastatic BRCA-Mutant Breast Cancer

December 11th 2015

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.

T-DM1 Extends Survival in Heavily Pretreated HER2+ Breast Cancer

December 11th 2015

T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.

Buparlisib Modestly Improves PFS in HR-Positive Advanced Breast Cancer

December 11th 2015

Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.

Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC

December 11th 2015

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).

APOBEC3B Overexpression Linked to Tamoxifen Resistance

December 11th 2015

The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.

Estrogen Receptor Mutations Linked to Lower Survival in HR+/HER2- Breast Cancer

December 11th 2015

Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.

Study Links pCR After Neoadjuvant Therapy to Improved Survival in TNBC

December 10th 2015

Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.

Complications, Costs Higher With Mastectomy Versus Lumpectomy for Early Breast Cancer

December 10th 2015

The risk of complications from mastectomy plus reconstruction was increased by two-fold compared with lumpectomy plus whole breast irradiation, after adjustment for other treatment differences.

Survival Better With Breast-Conserving Therapy Versus Mastectomy in Early-Stage Cancers

December 10th 2015

Women who opt for breast-conserving therapy and radiation to treat their early-stage breast cancer are about 20% more likely to be alive after 10 years compared with their counterparts who had mastectomy.

Reuben Harris on How Tamoxifen Resistance May be Driven by APOBEC3B

December 10th 2015

Reuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.

Atezolizumab/Nab-Paclitaxel Combo Shows High Response Rates in TNBC

December 10th 2015

Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.

NEXT PAGE
PREVIOUS PAGE